{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.49","upperLimit":"18.43","value":"7.16"},{"groupId":"OG001","lowerLimit":"3.88","upperLimit":"12.45","value":"8.16"},{"comment":"N/A=NE=not estimable, because of insufficient number of participants with events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG003","lowerLimit":"5.68","upperLimit":"7.39","value":"6.54"},{"groupId":"OG004","lowerLimit":"3.58","upperLimit":"22.14","value":"12.86"},{"comment":"N/A=NE=not estimable, because of insufficient number of participants with events","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A=NE=not estimable, because of insufficient number of participants with events","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG007","lowerLimit":"8.31","upperLimit":"30.98","value":"9.95"},{"comment":"N/A=NE=not estimable, because of insufficient number of participants with events","groupId":"OG008","lowerLimit":"13.08","upperLimit":"NA","value":"NA"},{"groupId":"OG009","lowerLimit":"2.40","upperLimit":"7.49","value":"3.42"},{"groupId":"OG010","lowerLimit":"3.48","upperLimit":"21.22","value":"9.92"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"9"},{"groupId":"OG010","value":"28"}],"units":"Participants"}],"description":"DOR was defined as the period from the date of initial PR or CR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria, until the date of PD or death from any cause. RECIST v1.1: PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. IMWG: PD: increase of \\>/= 25% from lowest response value in serum or urine M-protein or bone marrow plasma cell percentage or development of new or increase in size of bone lesions or soft tissue plasmacytomas.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC were treated with vemurafenib monotherapy.","id":"OG000","title":"Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib"},{"description":"Participants with ovarian cancer were treated with vemurafenib monotherapy.","id":"OG001","title":"Cohort 2: Ovarian Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib monotherapy.","id":"OG002","title":"Cohort 3a: Colorectal Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.","id":"OG003","title":"Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab"},{"description":"Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.","id":"OG004","title":"Cohort 4: Cholangiocarcinoma - Vemurafenib"},{"description":"Participants with multiple myeloma were treated with vemurafenib monotherapy.","id":"OG005","title":"Cohort 6: Multiple Myeloma - Vemurafenib"},{"description":"Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.","id":"OG006","title":"Cohort 7a: ECD/LCH - Vemurafenib"},{"description":"Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.","id":"OG007","title":"Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib"},{"description":"Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG008","title":"Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib"},{"description":"Participants with early stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG009","title":"Cohort 7d: Early Stage Astrocytoma - Vemurafenib"},{"description":"Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.","id":"OG010","title":"Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib"}],"paramType":"MEDIAN","populationDescription":"ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}